Tvardi Therapeutics Inc. (TVRD)
NASDAQ: TVRD
· Real-Time Price · USD
23.00
1.98 (9.42%)
At close: Apr 29, 2025, 3:56 PM
21.85
-5.00%
After-hours: Apr 29, 2025, 05:47 PM EDT
9.42% (1D)
| Bid | 20.12 |
| Market Cap | 215.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.25 |
| PE Ratio (ttm) | -10.22 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 21.85 |
| Volume | 54,148 |
| Avg. Volume (20D) | 10,513 |
| Open | 20.46 |
| Previous Close | 21.02 |
| Day's Range | 20.46 - 24.18 |
| 52-Week Range | 8.14 - 31.32 |
| Beta | 0.00 |
About TVRD
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC)....
Industry Biotechnology
Sector Healthcare
IPO Date Apr 16, 2025
Employees 17
Stock Exchange NASDAQ
Ticker Symbol TVRD
Analyst Forecast
According to 1 analyst ratings, the average rating for TVRD stock is "Buy." The 12-month stock price forecast is $39, which is an increase of 69.57% from the latest price.
Stock Forecasts